Keywords
Dear Editor,
The COVID-19 pandemic caused by Coronavirus-2 Acute Respiratory Syndrome (SARS-CoV-2) has incurred detrimental effects on health systems (1, 2). Given the desperate need to develop vaccines as quickly as possible, much effort has been made to develop and manufacture vaccines to prevent the transmission of COVID-19 to healthy individuals (3-5). Numerous studies have focused on medication therapy and patient recovery; however, vaccination will significantly affect the mortality rate by reducing infection with COVID-19 (3-9). Nonetheless, like any other compound, vaccines can also cause local and systemic complications (4-12).
The present study enrolled 100 healthcare providers of Shahid Mohammadi Hospital in Bandar Abbas city who had received the first dose of Gam-COVID-Vac (Sputnik V). The study was approved by the Ethics Committee of Hormozgan University of Medical Sciences (IR.HUMS.REC.1399.541). An online questionnaire was developed to assess demographic details and local and systemic complications of vaccination. These individuals were assessed at three time points: the first, third, and seventh days after vaccination in terms of local complications, including pain at the injection site, warmth, redness, and swelling, and systemic complications, including weakness and fatigue, headache, myalgia, bone pain, arthralgia, palpitation, diarrhea, nausea and vomiting, anorexia, coughing, sneezing, sore throat, runny nose, fever, chills, and urticaria. The participants were also followed for serious complications or mortality during one month after the first dose of vaccination.
Among the 100 participants studied, 10 had a history of infection with COVID-19 in the past six months. Among these 10 individuals, weakness and lethargy were observed in six individuals on day one, three individuals on day three, and one individual on day seven. Headache was reported by five individuals on day one, and one individual on day three. Myalgia was observed in eight individuals on day one, five individuals on day three, and two individuals on day seven. This complication was more frequent in participants with a history of COVID-19 compared to those without a history of COVID-19 in the past six months (80 vs. 53%). Bone pain was reported by eight individuals on day one, three individuals on day three, and one individual on day seven. Generally, this complication had a higher frequency percentage in those with a history of COVID-19 compared to those without it (80 vs. 43%). Anorexia was reported by three individuals on day one and one individual one day three (30% in group with a history of COVID-19 vs. 12% in group with no history of COVID-19).
Our results showed that 42% of the participants suffered from headaches on day one, 18% on day three, and 5% on day seven. Headache and asthenia were among the most common complications of the vaccine in a study by Logunov et al., in which a similar vaccine to that in the present study was used (5). The present study exhibited more cases of severe myalgia (Table 1). In another study, Zhu et al. reported myalgia in 18% of patients after vaccination with a similar dose (12).
Local and Systemic Complications of Gam-COVID-Vaccine on Days One, Three, and Seven
| Symptoms | Day 1 | Day 3 | Day 7 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asymptomatic | Mild | Moderate | Sever | Asymptomatic | Mild | Moderate | Sever | Asymptomatic | Mild | Moderate | Sever | |
| Weakness | 53 | 13 | 17 | 17 | 70 | 19 | 9 | 2 | 93 | 5 | 1 | 1 |
| Headache | 58 | 11 | 3 | 4 | 82 | 11 | 3 | 4 | 95 | 2 | 2 | 1 |
| Myalgia | 47 | 11 | 23 | 19 | 67 | 16 | 14 | 3 | 92 | 6 | 1 | 1 |
| Bone pain | 57 | 10 | 16 | 17 | 78 | 10 | 11 | 1 | 94 | 5 | 1 | 0 |
| Palpitation | 84 | 4 | 6 | 6 | 91 | 3 | 6 | 0 | 96 | 3 | 1 | 0 |
| Diarrhea | 95 | 3 | 2 | 0 | 93 | 5 | 2 | 0 | 98 | 1 | 1 | 0 |
| Nausea and Vomiting | 88 | 6 | 2 | 4 | 93 | 2 | 3 | 2 | 96 | 2 | 0 | 2 |
| Anorexia | 77 | 9 | 11 | 3 | 88 | 7 | 5 | 0 | 98 | 2 | 0 | 0 |
| Rhinorrhea | 93 | 5 | 2 | 0 | 96 | 2 | 1 | 1 | 97 | 1 | 2 | 0 |
| Sore throat | 91 | 5 | 4 | 0 | 92 | 6 | 2 | 0 | 96 | 2 | 1 | 1 |
| Fever | 68 | 20 | 5 | 7 | 91 | 8 | 1 | 0 | 100 | 0 | 0 | 0 |
| Chills | 64 | 11 | 10 | 15 | 91 | 6 | 3 | 0 | 99 | 1 | 0 | 0 |
| Urticaria | 95 | 4 | 1 | 0 | 99 | 1 | 0 | 0 | 100 | 0 | 0 | 0 |
| Warmth | 83 | 6 | 11 | 0 | 91 | 6 | 3 | 0 | 100 | 0 | 0 | 0 |
| Redness | 93 | 7 | 0 | 0 | 97 | 3 | 0 | 0 | 100 | 0 | 0 | 0 |
| Swelling | 92 | 4 | 3 | 1 | 98 | 2 | 0 | 0 | 100 | 0 | 0 | 0 |
Regarding the relationship between the history of COVID-19 in the past six months and vaccination complications, only myalgia and rhinorrhea on day one had a significant relationship with a positive history of COVID-19 in those receiving vaccination, but no significant relationship was noted between this variable on other days (days three and seven). The history of infection with COVID-19 had no significant association with other local complications.
With regard to adenovirus type-5 vaccine, a higher percentage of local and systemic complications were reported in the present study than in previous studies (5, 12). This difference can probably be attributed to the geographical, genetic, or sample size differences. Pain at the injection site was also the most common complication in inactivated SARS-COV-2 vaccines (11). Regarding mRNA-1273 vaccines, pain at the injection site was most frequently reported (10). Fatigue, headache, myalgia, and chills were the most common systemic complications of mRNA-1273-based COVID-19 vaccines (10). With regard to the relationship of history of COVID-19 and post-vaccination complications, rhinorrhea on day one, sneezing on day one, and sneezing on day three were observed in those with a history of COVID-19, respectively 9.5, 23, and 21 times higher than those without such a history. Although the history of COVID-19 was not investigated in their study, Baden et al. indicated that those who had COVID-19 at the time of vaccination experienced fewer complications than those who did not have COVID-19 (10).
In the present study, weakness, myalgia, headache, and pain at the injection site were the most frequently reported adverse reactions among people who received the first dose of Gam-COVID-vac. No serious complications or mortality was seen during the one-month follow-up.
References
-
1.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-62. [PubMed ID: 32171076]. [PubMed Central ID: PMC7270627]. https://doi.org/10.1016/S0140-6736(20)30566-3.
-
2.
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157-60. [PubMed ID: 32191675]. [PubMed Central ID: PMC7569573]. https://doi.org/10.23750/abm.v91i1.9397.
-
3.
Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945-6. [PubMed ID: 32385100]. https://doi.org/10.1126/science.abb8923.
-
4.
Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979-93. [PubMed ID: 33220855]. [PubMed Central ID: PMC7674972]. https://doi.org/10.1016/S0140-6736(20)32466-1.
-
5.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-81. [PubMed ID: 33545094]. [PubMed Central ID: PMC7852454]. https://doi.org/10.1016/S0140-6736(21)00234-8.
-
6.
Samimagham HR, Arabi M, Hooshyar D, KazemiJahromi M. The association of non-steroidal anti-inflammatory drugs with COVID-19 severity and mortality. Arch Clin Infect Dis. 2020;15(4). e106847. https://doi.org/10.5812/archcid.106847.
-
7.
Rahimi A, Samimagham HR, Azad MH, Hooshyar D, Arabi M, KazemiJahromi M. The efficacy of N-acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(1):271. [PubMed ID: 33845881]. [PubMed Central ID: PMC8040363]. https://doi.org/10.1186/s13063-021-05242-4.
-
8.
Samimagham HR, Hassani Azad M, Haddad M, Arabi M, Hooshyar D, KazemiJahromi M. The efficacy of famotidine in improvement of outcomes in hospitalized COVID-19 Patients: A phase III randomised clinical trial. Research Square. 2021;Preprint. https://doi.org/10.21203/rs.3.rs-462937/v1.
-
9.
Samimagham HR, Hassani Azad M, Haddad M, Arabi M, Hooshyar D, KazemiJahromi M. The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):848. [PubMed ID: 33050945]. [PubMed Central ID: PMC7552598]. https://doi.org/10.1186/s13063-020-04773-6.
-
10.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. [PubMed ID: 33378609]. [PubMed Central ID: PMC7787219]. https://doi.org/10.1056/NEJMoa2035389.
-
11.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39-51. [PubMed ID: 33069281]. [PubMed Central ID: PMC7561304]. https://doi.org/10.1016/S1473-3099(20)30831-8.
-
12.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479-88. [PubMed ID: 32702299]. [PubMed Central ID: PMC7836858]. https://doi.org/10.1016/S0140-6736(20)31605-6.